Skip to content

Clinical Trial of TMAO Determination Kit (LC-MS/MS)

Clinical Trial of TMAO Determination Kit (LC-MS/MS)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089774
Enrollment
Unknown
Registered
2024-09-14
Start date
2023-08-21
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney disease

Interventions

Gold Standard:Comparison method: eGFR. According to the Guidelines for Early Screening, Diagnosis, and Prevention of Chronic Kidney Disease (2022 Edition),eGFR[ ml·min- 1 ·(1.73 m2 ) -1 ]<60,If the du
Index test:TMAO Determination Kit (LC-MS/MS)

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age: 18~75 years old (including boundary values), both male and female; 2) Individuals who have been previously diagnosed with stage 1-5 chronic kidney disease and come to the hospital for regular creatinine check ups (stage 3-5 chronic kidney disease patients are not included in patients undergoing dialysis or planned transplantation), or those who come to the hospital for routine creatinine testing; 3) The subjects voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1) Individuals who have planned to use antibiotics within the past 4 weeks or before blood collection; 2) Individuals with a history of diarrhea within the past 4 weeks or who currently require medication to control the condition of diarrhea; 3) Has a history of surgery within the past 4 weeks; 4) Individuals who have planned to undergo enema within the past 4 weeks or before blood collection; 5) Perhaps due to other reasons, this experiment cannot be completed or the researcher believes that it should not be included.

Design outcomes

Primary

MeasureTime frame
TMAO;eGFR;Positive conformity rate;Negative conformity rate;

Secondary

MeasureTime frame
Total consistent rate;Kappa value;

Countries

China

Contacts

Public ContactZhang Hao

Third Xiangya Hospital of Central South University

zhanghaoliaoqing@163.com+86 139 7580 6919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026